



April 18, 2016

AnGes MG, Inc.

## Summary of the Announcement Regarding the Issue of Stock Acquisition Rights

Completion of the 27th Series of Stock Acquisition Rights  
(Private Placement) (with Option to Revise Exercise Price)

AnGes MG Inc. ("AnGes") announced that the exercise of the 27th Series of Stock Acquisition Rights issued to Mita Securities Co., Ltd. on April 11, 2016 is now complete. The following is a summary of the announcement.

1. Total number of shares issued: 6,436,700 shares
2. Total amount received: JPY 3,072,467,445 (including JPY 15,126,245 for the issuance of stock acquisition rights)

Date of Exercise	Number of Shares	Exercise Price (JPY)	Amount Received (JPY)
April 12	2,000,000	435* <sup>1</sup>	870,000,000
April 13	3,000,000		1,305,000,000
April 14	654,400		284,664,000
April 18	782,300	764* <sup>2</sup>	597,677,200

\*<sup>1</sup> Initial exercise price (92% of the closing price on March 24, 2016)

\*<sup>2</sup> Adjusted exercise price (92% of the closing price on April 14, 2016)

AnGes plans to apply the proceeds from the exercise of stock acquisition rights primarily for development costs in connection with NF-kB Decoy Oligonucleotide for atopic dermatitis (including the costs of Phase 3 clinical trials, chemistry, manufacturing and control costs, and other development costs) and in connection with NF-kB Decoy Oligonucleotide for disc degeneration (including the costs of Phase 1 and 2 clinical trials, chemistry, manufacturing and control costs, and other development costs).

###

AnGesMG, Inc.  
Corporate Communications  
TEL:+81-3-5730-2641, FAX:+81-3-5730-2635  
<http://www.anges-mg.com>